Zoetis Reports Q3 2026 Results, Narrows FY26 Revenue and Raises Adjusted EPS Guidance

Zoetis Inc. (NYSE: ZTS) Q3 2026 Financial Results Summary

Zoetis Inc. filed a Current Report on Form 8-K under Item 2.02 detailing its third-quarter financial results for 2026 and updating full-year guidance.

Key Financial Highlights

• Revenue: Reported revenue of $2.391 billion, down 1% on both a reported and organic operational basis compared to Q3 2025 ($2.422 billion).
• Net Income & GAAP EPS: GAAP net income was $591 million, a decrease of 18% YoY. Diluted EPS stood at $1.44, down 12% YoY.
• Adjusted Results: Adjusted net income was $720 million (down 5% reported, down 7% organic operational). Adjusted diluted EPS increased 3% to $1.75 (up 1% organic operational).

Segment Performance

• U.S. Segment: Revenue fell 6% YoY to $1.2 billion. Companion animal revenue decreased 8% due to macro-driven price sensitivity, dermatology competitive pressures, and generic alternatives, partially offset by a 5% increase in livestock revenue (cattle, swine, and poultry).
• International Segment: Revenue rose 4% YoY to $1.1 billion. Companion animal revenue increased 1% reported (flat organic operational), while livestock revenue grew 8% reported (9% organic operational), led by cattle and fish.

Updated FY 2026 Guidance

• Revenue: Narrowed to between $9.220 billion and $9.320 billion (organic operational growth of -2% to -1%).
• Adjusted Net Income: Raised to between $2.600 billion and $2.640 billion.
• Adjusted Diluted EPS: Raised to a range of $6.25 to $6.35.